Responding To The Changing Environment And External Forces Affecting The Pharmaceutical Industry

7:45 - Networking Breakfast And Conference Registration Networking Breakfast And Conference Registration

8:30 - Chairperson's Opening Remarks Jeff Totten, Vice President, Dean & Company Chairperson's Opening Remarks Jeff Totten Vice President, Dean & Company Jeffrey Totten is a Vice President of Dean & Company and head of its Life Sciences practice. Prior to joining the firm, Mr. Totten was a Principal with Mercer Management Consulting and one of the founders of its Life Sciences practice. Previously, Mr. Totten worked in Brand Management for the Procter & Gamble Company.Mr. Totten’s experience spans corporate and business strategy, market ent [read more]

8:45 - Keynote Panel: Taking The Financial Pulse Of The Pharma Market: Getting A Read On Where We Are And Where We're Headed Gregg Davis, Director, Worldwide Business Development, GlaxoSmithKline Juergen Lasowski, Senior Vice President, Business Development, Onyx Therapeutics George Bickerstaff, Managing Director, CRT Investments David Low, Managing Director, Lazard Gayle Mills, Executive Vice President, Business Development, ROXRO Pharma The ebb and flow of the financial markets has an immense impact on all industries and the pharmaceutical space is not immune. Understanding the investment landscape is essential to facilitating meaningful partnerships and ensuring that your company's goals are aligned with the broader industry focus. Securing financing in a dried up market- exploring innovative financing models available Analyzing emerging trends in the current market/economy Which therapeutic areas is the market moving towards? Which deal structures are being employed? How will the reimbursement environment affect VC investments and new company creation? Predicting timelines for when the IPO window will be open to all companies Combating the risk-averse public and private investment communities Gregg Davis Director, Worldwide Business Development, GlaxoSmithKline Juergen Lasowski Senior Vice President, Business Development, Onyx Therapeutics Juergen Lasowski, Ph.D., joined Onyx in May 2008 as senior vice president of corporate development. Before joining Onyx, he was the senior vice president of corporate development at NPS Pharmaceuticals. Previously, Dr. Lasowski held several positions at Sanofi-Aventis and its predecessor companies in business development and strategy positions. Throughout his career, Dr. Lasowski has completed ove [read more] George Bickerstaff Managing Director, CRT Investments George Bickerstaff joined CRT as Managing Director in 2005. CRT is an investment bank focused on funding and supporting domestic and international private and public companies. Prior to joining CRT, George was Chief Financial Officer of Novartis Pharma AG located in Basel, Switzerland.George has been instrumental in establishing the strategic, operating and financial direction of numerous private [read more] David Low Managing Director, Lazard Gayle Mills Executive Vice President, Business Development, ROXRO Pharma

9:45 - Keynote Panel: Adapting To The Changing State Of The Industry And Understanding The Impact On Deal-Making Robert Bagdorf, Worldwide Business Development, Pfizer Jules Musing, Vice President Licensing & Business Development, Johnson & Johnson Michael Lytton, Executive Vice President, Business Development, Biogen Idec Inc. Bill Bertrand, Senior Vice President, Legal Affairs, General Counsel and Corporate Compliance Officer, MedImmune Adelene Perkins, President & Chief Business Officer, Infinity We have already seen substantial changes in the Pharma/biotech space in the wake of the economic collapse. From evolving business models to industry consolidation, the environment has transformed rapidly. Yet, the affects of these changes on the industry remain to be seen. Representatives from all perspectives of the market will offer insight on the following: Evaluating the industry consolidation- will big Pharma control commercialization with R&D left to Biotechs? Determining the effect of the mega-mergers How will the increased bureaucracy and loss of talent due to redundancies affect innovation? Which organizational models best support: Productivity Innovation Efficiency Analyzing the different business models emerging Virtual Biotechs Is this the wave of the future for the Biotech space? Integrated Pharmaceutical Networks How will these more nimble organizations Lower operational costs? Increase R&D flexibility? Robert Bagdorf Worldwide Business Development, Pfizer Robert Bagdorf, M.D., MBA, is a board-certified neurologist who joined Pfizer in 1998 in CNS Clinical Development. For the past 8 years he has held positions of increasing responsibility within business development and currently oversees licensing and acquisition external search and evaluation activities for all therapeutic areas except Oncology.Prior to joining Pfizer, Dr. Bagdorf had a large con [read more] Jules Musing Vice President Licensing & Business Development, Johnson & Johnson Michael Lytton Executive Vice President, Business Development, Biogen Idec Inc. Michael Lytton is Biogen Idec's Executive Vice President, Corporate and Business Development, and has served in that position since February 2009. From 2001 to 2009, he was a General Partner at Oxford Bioscience Partners, a venture capital firm. From 1993 to 2000, he was Partner, Chairman of the Technology Group and a member of the Executive Committee of the law firm Edwards, Angell, Palmer & [read more] Bill Bertrand Senior Vice President, Legal Affairs, General Counsel and Corporate Compliance Officer, MedImmune Adelene Perkins President & Chief Business Officer, Infinity

10:45 - Refreshment Break & Networking Opportunity Refreshment Break & Networking Opportunity

11:30 - Navigating The Deal-Making Landscape Tim Herpin, Head of US Search, Bristol Myers Squibb John Hebert, Associate Director, Corporate Development, Genzyme Steven Damon, Senior Vice President, Business Development, Altea Therapeutics James Hattersley, Vice President, Business Development, Sun Pharmaceuticals Paul Darling, Principal, ZS Associates Building on the discussions from discussions from the previous sessions, which focused on the macro-environment and the major external factors affecting the Pharma space, this session will analyze how these impact deal-making and directly affect your day-to-day operations. Pinpointing the deal-making trends being employed in the current market and analyzing why they are successful Option deals Royalty monetization Mature drug deals Identifying the partnering atmosphere Who is partnering with whom? Mapping out the players that are the most active in the space Determining how the core partnering function has evolved given the current environment Tim Herpin Head of US Search, Bristol Myers Squibb Timothy Herpin, Ph.D. is currently Head of US Search in the Strategic Transactions Group at Bristol-Myers Squibb. In this role, he identifies partnering opportunities in the US across all of BMS’s disease areas. Prior to this position, Tim was responsible for licensing activities in the areas of cardiovascular and metabolic diseases, and before that he worked as a medicinal chemist at Bristol-Myer [read more] John Hebert Associate Director, Corporate Development, Genzyme Steven Damon Senior Vice President, Business Development, Altea Therapeutics James Hattersley Vice President, Business Development, Sun Pharmaceuticals Paul Darling Principal, ZS Associates Paul Darling is a Principal with ZS Associates, based in the firm’s San Francisco office. Paul has experience in a broad array of sales and marketing services and heads ZS's Business Development and Licensing practice. He assists clients in developing their disease area, portfolio planning, clinical development, and business development and licensing strategies. Paul primarily works with pharmaceu [read more]

12:30 - Partnering In The New Economy- Developing An Effective Alliance Management Function Within Your Company Mike Leonetti, Head, Health Care Partnerships, Boehringer Ingelheim Karen Denton, Director, Alliance Management, Bayer Healthcare Pharmaceuticals Alison Shurell, VP Product Marketing, Intralinks Partnering is clearly an integral part of your business and maintaining relationships to work efficiently and effectively over time is paramount. But what challenges will a changed economy pose to your partnering strategy? How do you ensure open communication, transparency and alignment throughout the partnership? This session will examine the value of the alliance management function in today’s environment as well as determine future partnering trends. Quantifying the value of the alliance management function in the new economy Citing specific examples of the benefits realized through effectively managing your relationships Measuring the success of an alliance- outlining the metrics to gauge effectiveness Collaborating across and within networks Leveraging tools to improve alliance management and team collaboration Analyzing the role of CROs/CSOs in future partnering models Mike Leonetti Head, Health Care Partnerships, Boehringer Ingelheim An accomplished Pharmaceutical Executive with 20 years of successful experience in a variety of key leadership capacities demonstrating diverse leadership skills to develop highly visible Health Care alliances resulting in multi billion dollar partnerships. As a long time employee with Boehringer Ingelheim, Mike has led multiple commercial functions including: Health Care Partnerships, Government [read more] Karen Denton Director, Alliance Management, Bayer Healthcare Pharmaceuticals Alison Shurell VP Product Marketing, Intralinks Alison Shurell is vice president of Life Sciences Product Marketing. She is responsible for building on IntraLinks position as the leading software as a service solution for critical information exchange in the Life Sciences industry. In this role, she partners with industry leaders in corporate development, clinical studies and regulatory affairs to help ensure the secure and efficient exchange o [read more]

1:10 - Lunch For All Conference Attendees Lunch For All Conference Attendees

2:25 - Case Study Part 1: Merck/Schering-Plough Merger Dr. Gregory J. Wiederrecht, Vice President & Head, External Scientific Affairs, Worldwide Licensing & External Research, Merck & Co., Inc. Over the past 18 months, there have been three notable mega-mergers in the pharmaceutical space, but it remains to be seen how these mergers will thrive and affect the industry. This case study will analyze the Merck/Schering-Plough merger in two parts. Part 1 of our 2 part series will delve into the motivations and rationale behind the strategic choice to combine these two Pharma giants and discuss the following themes: Overview of the strategic considerations that led to the deal Analyzing the ins and outs of the negotiation process Determining the internal take-aways and lessons learned from both parties A look at the status of the relationship today In order to fully assess the impact of the merger, Part 2 of our case study will take place at BioNetwork West 2010. This will allow us to look at hard data in terms of impact vs. expectations of the merger. Dr. Gregory J. Wiederrecht Vice President & Head, External Scientific Affairs, Worldwide Licensing & External Research, Merck & Co., Inc. Dr. Greg Wiederrecht is the Vice President and Head of External Scientific Affairs (ESA) in the Merck Research Laboratories division of Merck & Co., Inc. where he has been employed for the past 20 years. ESA is responsible for the scientific assessment of all licensing, partnering, and acquisition opportunities for Merck. Dr. Wiederrecht’s responsibilities include the management of a group of [read more]

3:10 - Refreshment Break & Networking Opportunity Refreshment Break & Networking Opportunity

3:55 - Case Study: J&J’s Acquisition Of Elan’s Alzheimer’s Immunotherapy Program (AIP) Patrick Verheyen, Vice President, Business Development, Johnson & Johnson This case study will discuss the unique deal structure between pharmaceutical giant J&J and Irish drug-maker Elan. The session will delve into the strategic motivations behind J&J’s $885 million stock buyout and innovative asset purchase agreement around Elan’s most advanced Alzheimer’s disease programs. Patrick Verheyen Vice President, Business Development, Johnson & Johnson

4:40 - Bracing For The Generic’s Market Entry- Biosimilars And The Pending Patent Cliffs Jennifer Tegfeldt, Director Business Initiatives & Strategies, Genzyme Everyone invested or involved in the Pharma space is keenly aware of the approaching patent cliff and the imminent entry of generics into the branded space. This issue is compounded by the pending legislation for the biosimilar market entrance. With Big Pharma’s pipelines already low and the mounting costs of biologics, all eyes are on the generics space. This panel of experts will evaluate the following points: Analyzing the exclusivity period for biologics and the impact on the market Will biosimilars have the same impact as generics on the branded space? Is the US likely to adopt the European model for biosimilars? Off-setting the entrance of the generic market to protect ROI What other revenue streams are being explored? How is Pharma refilling its pipeline? Which therapeutic areas are the focus? What projects are being invested in? Jennifer Tegfeldt Director Business Initiatives & Strategies, Genzyme

5:20 - Cocktail Reception Join all speakers and attendees for an intimate cocktail reception overlooking the beautiful South Beach. Everyone knows the best conversations are had with a cocktail in hand.